Best of ASCO - 2014 Annual Meeting

 

Welcome

New Targets and New Technologies

Tumor Biology

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
3D spheroid invasion drug screen platform for pancreatic ductal adenocarcinoma.

Claire Wells

e24212

A CODAR-PCR assay using nucleic acids extracted from whole blood samples to provide superior sensitivity in EGFR T790M mutation detection and accurate prediction of osimertinib response in advanced NSCLC patients.

Qiong Zhao

e24221

A novel multi-functional KDM1A chemoprobe as a tool for clinical cancer research.

Filippo Ciceri

e24242

A phase 1/2 dose-escalation and expansion study of a conditionally active anti-AXL humanized monoclonal antibody (BA3011) in patients with advanced solid tumors.

Jordi Rodon Ahnert

TPS12126

A universal high-throughput liquid biopsy technique for rare tumor cells recovery from various body fluids.

Yaoping Liu

e24224

Adenoviral shRNA vector targeting ribonucleotide reductase M1 (RRM1) has a strong antitumor activity and decrease the drug resistance to GEM in RRM1-overexpressing bladder cells.

Xia Zhang

e24237

Ado-trastuzumab emtansine (T-DM1) in patients (pts) with HER2 amplified (amp) tumors excluding breast and gastric/gastro-esophageal junction (GEJ) adenocarcinomas: Results from the National Cancer Institute (NCI) Molecular Analysis for Therapy Choice (MATCH) trial.

Komal L. Jhaveri

100

Bifidobacterium with mycosporin-like amino acid: A new model for oncogenesis.

Fatih Kose

e24204

Biological role of TUSC3 in non-small-cell lung cancer.

Jianxue Zhai

e24213

Cancer genomics-based screening of new therapeutic targets and biomarkers for lung cancer.

Yataro Daigo

12078

Cardioprotective effects of nanoemulsions loaded with natural anti-inflammatory bioactives against doxorubicin-induced cardiotoxicity in rat cardiomyocytes.

Vincenzo Quagliariello

e24227

Chimeric antigen receptor T cells targeting the lambda light chain of human immunoglobulin as a viable target for B cell non-Hodgkin lymphoma.

Raghuveer Ranganathan

12079

Clinical applicability of comprehensive genomic profiling (CGP) and assessment of tumor mutation burden (TMB): An Indian experience.

Amit Verma

e24210

Clinicopathologic characteristics and molecular features of BRG1-deficient non-small cell lung cancer (NSCLC).

Ibiayi Dagogo-Jack

12083

Correlation of radiomic features with PD-L1 expression in early stage non-small cell lung cancer (ES-NSCLC) to predict recurrence and overall survival (OS).

Pradnya Dinkar Patil

e24247

Detection of targetable fusions using FusionPlex in oncology patients.

Su Jin Lee

e24238

E2 to enhance the ability of doxorubicin to disturb iron homeostasis, induce cell cycle arrest and apoptosis in breast and ovarian cancer cell lines.

Khuloud Bajbouj

e24225

Early assessment of treatment effect in advanced lung adenocarcinoma via longitudinal ctDNA analysis.

Xiaoju Max Ma

12088

Effect of anti-PD-1 and anti-Id-1 combo on tumor response and survival in lung cancer.

Iosune Baraibar

12085

Effect of metabolic syndrome on risk of recurrence and immune pathways in invasive lobular carcinoma disparately compared to ductal.

Patricia A. Robinson

e24229

Effect of the TGFβ induced lncRNA TBILA on non-small cell lung cancer progression by regulating HGAL and binding with S100A7.

Zhiliang Lu

e24203

Evaluation of an intratumorally administered slow release docetaxel formulation in combination with systemic anti-PD-1 treatment in a preclinical model.

Martin Johansson

e24214

Evaluation of drug sensitivity and tumor heterogeneity in thoracic cancers using CANScript, a novel ex-vivo tumor platform.

Arun Rajan

e24246

Gene expression signature development to decode breast cancer heterogeneity.

Heather Ann Brauer

e24243

Genetic and chemical screens in 2-D vs. 3-D generate distinct leads for target and drug discovery.

Piyush Gupta

12087

Genetic mutation as biomarker for advanced cancer patients receiving apatinib: An analysis based on whole exome sequencing.

Yong Fang

e24219

Identification of genes associated resistance of everolimus in cutaneous squamous cell carcinoma.

Jonggwon Choi

e24208

Incidence of Neuregulin1 (NRG1) gene fusions across tumor types.

Stephen V. Liu

12084

Local drug activation technology to make cytotoxics safer for localized solid tumors.

Sangeetha Srinivasan

12082

MCL-1 expression of non-small cell lung cancer as a prognostic factor and MCL-1 as a promising target for gene therapy.

Takayuki Nakano

e24236

Modified ketogenic diet in lymphoma: A case series in the Veteran Affairs Pittsburgh Healthcare System.

Jocelyn Tan-Shalaby

e24222

Mutation profiling of TSC1 and TSC2 genes in solid tumors using comprehensive NGS panel.

Yong Li

e24244

Mutation profiling of FGFR genes in solid tumors using comprehensive NGS panel.

Lingjun Zhu

e24241

New drug AIMPILA targeted to AFP receptor: Oral anticancer therapy and biodistribution in vivo.

Sergei Tsurkan

e24232

Next generation sequencing in non metastatic high grade pediatric osteosarcoma: A useful tool to identify new therapeutic targets.

Elise Lavit

e24235

Novel ex vivo patient-derived 3D model as a powerful tool to apply precision medicine.

Kayla Simeone

12086

Novel technology, high sensitive tissue testing, to analyze intra-tumor pharmacokinetics of anti-HER2 antibody drugs in breast cancer.

Mitsuhiro Hayashi

e24228

PRC-2 epigenetic chromatin reprogramming in ALK-positive (ALK+) lung cancer initial emergence of precision drug resistance.

Patrick C. Ma

12020

Preclinical efficacy studies of DS-1062a, a novel TROP2-targeting antibody-drug conjugate with a novel DNA topoisomerase I inhibitor DXd.

Daisuke Okajima

e24206

Preclinical evidence for management of thrombocytopenia associated with bromodomain extra-terminal (BET) inhibition therapy.

Srinivasa R Mantena

e24207

Role of PD-L1 expression in triple-negative breast cancer stem cells.

Massimo A. Di Nicola

12081

Sphingosine-1-phosphate to regulate cancer apoptosis by modulating cathelicidin production.

Shivtaj Mann

e24202

Successful generation of patient derived xenografts and patient derived 3D cultures as preclinical models for breast cancer.

Verena Imke Isabel Kiver

12080

Targeting the Hedgehog signalling pathway in triple negative breast cancer.

Mun Ngah Hui

e24216

TEAPOT, a quantitative approach to address intra-tumor heterogeneity by identifying driver mutations in cancer cell subpopulations.

Jianshu Zhang

e24215

The predicted potential of quantitative t cell repertoire analysis using next-generation sequencing in anti-PD-L1 treatment in NSCLC patients.

Qiong Zhao

e24220

VariantPlex panel to detect genomic aberrations in oncology patients with rare cancer type.

Su Jin Lee

e24234

WINTHER: An international WIN Consortium precision medicine trial using genomic and transcriptomic analysis in patients with advanced malignancies.

Jordi Rodon

12011